Patents by Inventor Steven M. Stirdivant

Steven M. Stirdivant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11932854
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: March 19, 2024
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
    Publication number: 20230030119
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: April 1, 2021
    Publication date: February 2, 2023
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)
    Publication number: 20220195433
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (MAO against target gene expression.
    Type: Application
    Filed: October 25, 2021
    Publication date: June 23, 2022
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 11193126
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 7, 2021
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
    Publication number: 20190330639
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: February 8, 2019
    Publication date: October 31, 2019
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 10246714
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: April 2, 2019
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20180362977
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: April 6, 2018
    Publication date: December 20, 2018
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 9970005
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 15, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, William Michael Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
    Publication number: 20180030454
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: August 8, 2017
    Publication date: February 1, 2018
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 9850491
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that medium RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 26, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
    Publication number: 20170029824
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that medium RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: August 1, 2016
    Publication date: February 2, 2017
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (SINA)
    Patent number: 9447420
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: September 20, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20160264964
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: December 30, 2015
    Publication date: September 15, 2016
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Mark Cancilla, James John Cunningham, Michael William Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham
  • BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME
    Publication number: 20160245814
    Abstract: Methods for identifying and evaluating biochemical entities useful as biomarkers for kidney cancer are described. Suites of small molecule entities as biomarkers for clear cell papillary kidney cancer are also described.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 25, 2016
    Inventors: Bruce NERI, Steven M. STIRDIVANT
  • RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
    Patent number: 9260471
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 16, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Mark Cancilla, James J. Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron Willingham
  • RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
    Publication number: 20140343126
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 20, 2014
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 8835623
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
    Publication number: 20130324588
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
    Patent number: 8518907
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: August 27, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Duncan Brown, James J. Cunningham, Marian Gindy, Victoria Pickering, Matthew G. Stanton, Steven M. Stirdivant, Walter R. Strapps
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
    Publication number: 20130217756
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 22, 2013
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Mark Cancilla, James John Cunningham, Michael W. Flanagan, Henry J. Haringsma, Denise M. Kenski, Matthew G. Stanton, Steven M. Stirdivant, Aarron T. Willingham